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ABSTRACT
Objective: To evaluate the efficacy of Memantine as a therapeutic intervention for fibromyalgia. Methods: This clinical
trial was conducted between October 2014 and December 2014. A total of 30 subjects with diagnosed fibromyalgia
presenting to a private neurology clinic in Karachi, Pakistan were selected through purposive sampling technique. Adult
patients belonging to both genders were included in the study. Patients were treated with incremental doses of
Memantine. Data was analyzed using SPSS version 20 and associations were made using Chi square test with p-value
of less than 0.05 taken as significant. Results: Out of 30 patients, 2 (6.7%) were males and 28 (93.3%) were females
which shows a very high occurrence of fibromyalgia in females. The mean age of the subjects was found to be 38 years.
Efficacy of the drug in patients with fibromyalgia was observed to be 93.3% which is significantly high. The baseline FIQ
score when compared with the score at 3-month follow-up by applying Wilcoxon signed rank test showed mean ± S.D
(67.18±13.23 vs. 34.17±15.18) where p=0.000. This shows a highly significant result (≤0.05). All of the patients
with fibromyalgia reported improvement in their physical functioning and majority of the patients felt less anxious and
less depressed on their final follow-up visit. By the end of the 3rd month, the level of stiffness and intensity of pain
decreased significantly and patients reported less difficulty in performing work. Conclusion: Memantine has shown
significant beneficial effects in reducing the intensity of pain and disability in patients with fibromyalgia.
KEY WORDS: Memantine, Fibromyalgia, Efficacy.
INTRODUCTION

neuron.2,8,9,10 Hence, Memantine has the potential to
block excessive NMDA glutamate receptor activity and
thus prevents excitatory amino acid neurotoxicity,
without disrupting the intellectual capacity regulated by
the physiological actions of glutamate. Memantine, a
low-affinity antagonist to NMDA glutamate receptors
that are thought to be intrinsic to pain transmission,
has also been shown to be effective in the treatment of
migraine and tension-type headache.11,12,13,14 The
excitatory neurotransmitters, like glutamate, have been
suggested to play an important role in potentiation and
augmentation of the pain transmission cascade in
chronic headache states in the same way these
neurotransmitters are involved in signal transmission to
spinal cord or brainstem in chronic pain conditions.11
Memantine has also shown potential in addressing the
issues of complex regional pain syndrome and phantom
limb pain, which suggests that its effectiveness in
relieving pain depends on the kind of pain under
consideration.15 Cognitive problems have often been
reported by patients with chronic pain disorders.
Memantine, being a glutamate receptor antagonist, has
the capacity to tackle both of these problems.13

Memantine has been in use in the US and Europe for
neurocognitive disorders for quite some time. The three
most common forms of dementia affecting old-aged
people are Alzheimer’s disease, vascular dementia and
mixed dementia.1 Excitatory neurotransmitters, like
L-glutamate and its receptor subtypes, have been
shown to play a role in pathogenesis of Alzheimer’s
disease as well as in promoting pain mechanisms.
Memantine works as a low-affinity, voltage-dependent,
uncompetitive antagonist at N-methyl-D-aspartate
(NMDA) glutamate receptors.2,3,4 By binding to the
NMDA receptor with a higher affinity than Mg2+ ions,
Memantine inhibits the prolonged influx of Ca2+ ions
which forms the basis of neuronal excitotoxicity. The low
affinity, uncompetitive nature, and rapid dissociation
rate of Memantine allows it not to accumulate
substantially in the synaptic channels, hence, it does
not interfere with the normal synaptic transmission.5,6,7
This preserves the function of the receptor at synapses,
allowing it to be activated by physiological releaseof
glutamate following depolarization of the presynaptic
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analgesics such as Tramadol or Acetaminophen.
Patients already taking Memantine, Another Axis I
psychiatric disorder using Structured Clinical Interview
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere
with adherence to the study protocol (e.g. alcohol
and/or substance abuse/dependence, schizophrenia,
chronic delirium, acute depression etc.) Pregnancy or
breast-feeding. Hypersensitivity to the active ingredient,
Memantine. Evidence of clinically significant liver or
kidney disease, hematological, respiratory, endocrine or
cardiovascular disorders. Use of NMDA receptor
antagonists (amantadine, ketamine, dextromethorphan),
L-Dopa, dopamine agonists, cholinergic agonists and other
prescription drugs that may cause drug interactions with
Memantine. Use of antidepressants (duloxetine,
venlafaxine, mirtazapine, bupropion, SSRI, etc.),
analgesics (pregabalin, gabapentin, opiates, etc.) or
other non-permitted concomitant medications.

Further more, in several clinical trials, Memantine has
shown very low incidents of adverse effects.16,17
Treatment for fibromyalgia has limited efficacy, with an
effect size of about 0.5. Several studies conducted on
patients with fibromyalgia have demonstrated increased
concentration of glutamate in the insula, hippocampus
and posterior cingulate cortex regions of the brain of
these patients. This has led a number of authors to
suggest the efficacy of glutamate antagonists such as
Memantine in the treatment of fibromyalgia.18 The
aforementioned wide variety of uses of Memantine in
the field of medicine has greatly increased the interest
of researchers in this revolutionary drug. Our area of
interest is to find out the efficacy of Memantine in the
treatment of fibromyalgia. To the best of our knowledge,
no study has been conducted in our part of the world
about the use of NMDA antagonists that could be of
major interest in regards to the pathophysiology and
future treatment of fibromyalgia.

Each patient diagnosed to have fibromyalgia coming to
the outpatient department was explained about the
purpose of the study including the risks and benefits of
participation in the study. After obtaining signed
consent, intervention was started. Patients received
20mg of Memantine (2 tablets of 10 mg each). The
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily
Patients were followed upinitially at 1stweek, 2ndweek,
then every month for a total of three months. On each
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ)
was filled for patients with fibromyalgia and patients
were observed for the efficacy of the drug.

OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the
patientcomplains of muscle aches and stiffness with
trigger points on palpation and non-refreshing sleep.
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia
presenting to Neuro Clinic and Care, a private neurology
clinic in Karachi, Pakistan were selected through
purposive sampling technique. Data was collected over
a period of three months between October 2014 and
December 2014.

Outcome measures:

Inclusion criteria included:

Improvement in clinical variables. To assess improvement
in health status of patients with fibromyalgia from the
baseline and relatively from each previous visit at 1st
week, 2nd week, 1st month, 2nd month, and 3rd month
using FIQ20. FIQ is a 10-item questionnaire to measure
the health status in patients with fibromyalgia.

Adult patients of both genders. Diagnosis of Fibromyalgia
using American College of Rheumatology Criteria for
Diagnosis of Fibromyalgia19. Signature of Informed
Consent Form. In case of females of childbearing age,
commitment not to become pregnant during the entire
duration of the study.

Interpretation:
0 to < 39 – Mild effect
≥39 to < 59 – Moderate effect
≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis.
Separate frequencies and percentages were calculated
for categorical variables. Association was assessed
through Chi square test and p-value ≤0.05 was taken
as significant.

Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing
drug treatment for fibromyalgia. Patients already
receiving treatment will stop treatment and a washout
period of one week will be performed. During the wash
out period the patient may take, if necessary,
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RESULT

FIQ score at the final visit relative to the initial visit. Out
of 28 patients who showed improvement, 1 had mild, 5
had moderate and 22 had severe disease. Efficacy of
the drug was found to be 93.3% which is significantly
high. The baseline FIQ score when compared with the
score at 3-month follow-up by applying Wilcoxon signed
rank test showed mean ± S.D (67.18±13.23 vs.
34.17±15.18) where p=0.000 (<0.05) which shows
a highly significant result. All of the 30 patients reported
improvement in their physical functioning at the final
follow-up visit three months. 26 (86.7%) out of 30
patients stated that they felt better relative to their
emotional status at the initial visit. 24 (80%) patients
said that they missed less number of days at work,
including housework, because of fibromyalgia symptoms
after taking the drug. 28 (93.3%) patients reported less
difficulty performing work and less interference of
fibromyalgia symptoms with their ability to do work as
compared to the baseline. Same percentage of the
patients said that the level of stiffness had decreased
after taking Memantine. Almost all (29, 96.7%) patients
reported improvement in pain and waking up well rested in
the morning after taking Memantine. 27 (90%) patients
reported improvement in fatigue and anxiety at the final
follow-up visit at three months. Improvement in symptoms
of depression was noted by 26 (86.7%) patients.

FIGURE 1: IMPROVEMENT IN FIQ SCORE FROM BASELINE
TO 3-MONTH FOLLOW-UP
Better
93%
Same
0%
Worse
7%

Out of 30 patients, there were 6.7% (2) of males and
93.3% (28) of females which shows a very high
occurrence of fibromyalgia in females. Average age of
the subjects was 37.6 ≈ 38 years. The baseline FIQ
score was classified on the basis of severity.21Out of
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%)
patients had moderate and 24 (80%) patients had
severe disease. Follow-up at the end of the 1st week
showed improvement in only 13.3% (4) of the patients
according to the FIQ score. All of these patients had
severe disease. 60% (18) of the patients revealed
improvement in their FIQ scores compared to the
previous visit at the end of the 2nd week. Of these 18
patients, 1 had moderate and 17 had severe disease.
At the end of the 1st month, 86.7% (26) of the patients
reported improvement in their health status and quality
of life from the previous visit, which was also
demonstrated by the improvement in their FIQ score. At
the end of the 2nd month, 83.3% (25) of the patients
had further improvement in their FIQ score as
compared to the score at the 1-month follow-up visit
and the same percentage of patients had improvement
in their FIQ score at the final follow-up visit at three
months compared to their score at 2-month follow-up.
Out of these 25 patients, 3 had moderate and 21 had
severe disease. As depicted in Table 1, out of 30
patients, 5 (16.7%) patients showed improvement in
their FIQ score at 1-week follow-up. All of these patients
were females and suffered from severe disease. At
2-week follow-up, 18 (60%) patients had improvement
in the FIQ score from the baseline. 28 (93.3%) patients
demonstrated improvement in their FIQ score at the
end of one month as compared to the baseline and the
same percentage of patients had better FIQ score than
the baseline score at the end of two months. At the
final follow-up visit at three months, 28 (93.3%)
patients had improvement in their FIQ score from the
baseline, of which 2 were males and 26 were females.
2 patients who had severe disease had worsening of
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DISCUSSION
The present study sought to demonstrate the efficacy of
Memantine in the treatment of fibromyalgia. According to
a randomized controlled clinical trial conducted on 25
patients with fibromyalgia to evaluate the efficacy of
Memantine on metabolite levels in the brain, patients
treated with Memantine exhibited an increase in cerebral
metabolism of glutamate and other metabolites, which
suggests its potential role in the treatment of
fibromyalgia.22 A number of studies have been conducted
to evaluate the potential role of NMDA glutamate receptor
antagonists like Memantine, Ketamine, Amantadine and
Dextromethorphan in the treatment of neuropathic pain
and other kinds of chronic pain.6,7 In a six-month long
randomized controlled trial carried out in Spain on 63
patients with fibromyalgia who were administered 20
mg/day of Memantine after 1 month of titration, significant
improvement in pain, quality of life, global functioning and
depression was noted.23 In the present study, all of our
patients reported improvement in their physical functioning
at the final follow-up visit at 3 months and almost all
(96.7%) patients reported improvement in pain and
waking up well rested in the morning after taking
Memantine. 28 (93.3%) patients reported less difficulty
performing work and less interference of fibromyalgia
symptoms with their ability to do work as compared to the
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Table 1: Improvement in FIQ Score from Baseline to follow-up at 1 Week, 2 Weeks, 1 Month, 2 Months and 3 Months
S.No.

Baseline FIQ
Score

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

80
42
76.3
81.4
32
77.5
69.4
67.8
71.4
63.1
69
71.1
85.9
77.6
68.5
65.3
78.2
76.9
85.1
65
52
68.6
41.8
57.6
59.3
75
70.3
75.2
65.3
46.8

Improvement at
1st week
%
0
0
0
0
3(deterioration)
0
0
0
0
0
0
10
0
5
6
0
2
0
0
0
4
0
0
0
0
0
0
0
0
0

Improvement at
2nd week
%
0
0
17
7
3(deterioration)
0
0
0
10
14
9
16
27
50
10
19
56
20
54
27
22
0
0
0
35
4(deterioration)
15
0
19
0

baseline. Same percentage of the patients said that the
level of stiffness had decreased after taking Memantine.
90% of the patients reported less fatigue and anxiety at
the final follow-up visit at 3 months. Improvement in
symptoms of depression was noted by 86.7% of the
patients. Some of the patients (80%) said that they
missed less number of days at work, including house work,
because of fibromyalgia symptoms after taking the drug.
Another double-blind, randomized, controlled clinical trial
conducted byOlivan-Blazquezto evaluate the efficacy of
Memantine in the treatment of pain in patients with
fibromyalgia showed that after 3 months of treatment with
20 mg/day of Memantine after titration for 1 month,
patients exhibited significant improvement in cognitive
decline, symptoms of depression and global functioning. 18
In our study, at 2-week follow-up, more than half of the
patients (60%) exhibited improvement in their FIQ score
relative to the baseline. Almost all of the patients (93.3%)
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Improvement at
1st month
%
48
18
23
12
3
13
16
24
10
14
21
33
43
54
36
20
61
31
57
34
37
0
49
22
43
4(deterioration)
25
24
20
49

Improvement at
2nd month
%
61
31
31
18
18
25
20
31
31
41
32
39
43
68
56
33
73
51
64
51
43
2
49
28
64
4(deterioration)
36
26
33
49

Improvement at
3rd month
%
73
54
36
40
32
30
29
43
37
52
41
57
65
75
58
55
73
57
69
70
62
2
49
46
73
4(deterioration)
50
41
55
49

demonstrated improvement in their FIQ score as
compared to the baseline at the end of 1 month. The
baseline FIQ score when compared with score at 3-month
follow-up by applying Wilcoxon signed rank test showed
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity
in patients with fibromyalgia.24 Several studies have shown
the efficacy of Memantine in improving symptoms of
depression in fibromyalgia patients.18, 23 86.7% of the
patients in our study reported less or none symptoms of
depression at the final follow-up visit at three months. A
number of studies have demonstrated that the incidence
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The
fact that the drug is well-tolerated has been shown in our
study as well. In our study, none of the patients developed
significant adverse effects to warrant exclusion from the
study. Although additional studies that are randomized,
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controlled, conducted on a larger sample size and with a
longer follow-up time frame are needed, the present study
provides preliminary evidence regarding efficacy of
Memantine in the treatment of fibromyalgia.

9.

CONCLUSION
10.

Memantine is an effective drug for the treatment of
fibromyalgia in terms of improving cognitive functions as
demonstrated by the drastic improvement in the overall
health status and quality of life in patients with
fibromyalgia as evidenced by the improvement in FIQ
score. A randomized, placebo-controlled, double-blind
clinical trial conducted on a larger sample size is
needed to confirm our observations.

11.
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